Diagnostic performance of zero-TE lung MR imaging in FDG PET/MRI for pulmonary malignancies

PurposeThis study aims to determine the diagnostic performance of whole-body FDG PET/CT plus delayed abdomen PET/MR imaging in the pretherapeutic assessment of pancreatic cancer in comparison with that of contrast-enhanced (CE)-CT/MR imaging.Materials and MethodsForty patients with pancreatic cancer underwent nonenhanced whole-body FDG PET/CT, delayed abdomen PET/MR imaging, and CE-CT/MR imaging. Two nuclear medicine physicians independently reviewed these images and discussed to reach a consensus, determining tumor resectability according to a 5-point scale, N stage (N0 or N positive), and M stage (M0 or M1). With use of clinical-surgical-pathologic findings as the reference standard, diagnostic performances of the two imaging sets were compared by using the McNemar test.ResultsThe diagnostic performance of FDG PET/CT plus delayed PET/MR imaging was not significantly different from that of CE-CT/MR imaging in the assessment of tumor resectability [area under the receiver operating characteristic curve: 0.927 vs. 0.925 (p = 0.975)], N stage (accuracy: 80% (16 of 20 patients) vs. 55% (11 of 20 patients), p = 0.125), and M stage (accuracy: 100% (40 of 40 patients) vs. 93% (37 of 40 patients), p = 0.250). Moreover, 14 of 40 patients had liver metastases. The number of liver metastases detected by CE-CT/MR imaging, PET/CT, and PET/MR imaging were 33, 18, and 61, respectively. Compared with CE-CT/MR imaging, PET/MR imaging resulted in additional findings of more liver metastases in 9/14 patients, of which 3 patients were upstaged. Compared with PET/CT, PET/MR imaging resulted in additional findings of more liver metastases in 12/14 patients, of which 6 patients were upstaged.ConclusionsAlthough FDG PET/CT plus delayed PET/MR imaging showed a diagnostic performance similar to that of CE-CT/MR imaging in the pretherapeutic assessment of the resectability and staging of pancreatic tumors, it still has potential as the more efficient and reasonable work-up approach for the additional value of metastatic information provided by delayed PET/MR imaging.

Download Full-text

A New Diagnostic Criterion with Gadoxetic Acid-Enhanced MR Imaging May Improve the Diagnostic Performance for Hepatocellular Carcinoma

SSRN Electronic Journal ◽

10.2139/ssrn.3449355 ◽

2019 ◽

Author(s):

Yi Wei ◽

Zheng Ye ◽

Yuan Yuan ◽

Zixing Huang ◽

Xiaocheng Wei ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Mr Imaging ◽

Diagnostic Performance ◽

Gadoxetic Acid ◽

Diagnostic Criterion

Download Full-text

FDG PET/MR Imaging in Major Neurocognitive Disorders

Current Alzheimer Research ◽

10.2174/1567205013666160620115130 ◽

2017 ◽

Vol 14 (2) ◽

pp. 186-197 ◽

Cited By ~ 8

Author(s):

Ismini Mainta ◽

Daniela Perani ◽

Benedicte Delattre ◽

Frederic Assal ◽

Sven Haller ◽

...

Keyword(s):

Mr Imaging ◽

Fdg Pet ◽

Neurocognitive Disorders

Download Full-text

Diagnostic performance of 18F-FDG PET/CT, ultrasonography and MRI

Nuklearmedizin ◽

10.3413/nukmed-0605-13-06 ◽

2014 ◽

Vol 53 (03) ◽

pp. 89-94 ◽

Cited By ~ 17

Author(s):

D. H. Lee ◽

J.-K Yoon ◽

S. J. Lee ◽

T. H. Kim ◽

D. K. Kang ◽

...

Keyword(s):

Lymph Node ◽

Fdg Pet ◽

Axillary Lymph Node ◽

Diagnostic Performance ◽

Axillary Lymph ◽

Diagnostic Ability ◽

Node Metastasis ◽

Pet Ct ◽

18F Fdg ◽

Fdg Pet Ct

SummaryThe aim of this study was to evaluate the diagnostic abilities of 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) compared with those of ultrasonography and magnetic resonance imaging (MRI) for axillary lymph node staging in breast cancer patients. Patients, methods: Pre- operative 18F-FDG PET/non-contrast CT, ultrasonography and MRI were performed in 215 women with breast cancer. Axillary lymph node dissection was performed in all patients and the diagnostic performance of each modality was evaluated using histopathologic assessments as the reference standard. ROC curves were compared to evaluate the diagnostic ability of several imaging modalities (i. e., ultrasonography, MRI and 18F-FDG PET/CT). Results: In total, 132 patients (61.4%) had axillary lymph node metastasis. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for the detection of axillary lymph node metastasis were 72.3%, 77.3%, 66.7%, 81.6%, 75.3% for ultrasonography, 67.5%, 78.0%, 65.9%, 79.2%, 74.0% for MRI, and 62.7%, 88.6%, 77.6%, 79.1%, 78.6% for 18F-FDG PET/CT, respectively. There was no significant difference in diagnostic ability among the imaging modalities (i.e., ultrasonography, MRI and 18F-FDG PET/CT). The diagnostic ability of 18F-FDG PET/CT was significantly improved by combination with MRI (p = 0.0002) or ultrasonography (p < 0.0001). The combination of 18F-FDG PET/CT with ultrasonography had a similar diagnostic ability to that of all three modalities combined (18F-FDG PET/CT+ultraso- nography+MRI, p = 0.05). Conclusion: The diagnostic performance of 18F-FDG PET/CT for detection of axillary node metastasis was not significantly different from that of ultrasonography or MRI in breast cancer patients. Combining 18F-FDG PET/CT with ultrasonography or MRI could improve the diagnostic performance compared to 18F-FDG PET/CT alone.

Download Full-text